<DOC>
	<DOCNO>NCT02856100</DOCNO>
	<brief_summary>We intend validate 18F-DCFPyL imaging patient metastatic , castrate-resistant PCa ( CRPC ) , may use full advantage support exist emerge therapy spectrum patient suffer PCa . In study image patient CRPC undergo second-line anti-androgen therapy ( enzalutamide abiraterone ) use 18F-DCFPyL-PET/CT detection metastases therapeutic monitoring , correlation standard-of-care conventional imaging modality ( CIM ) ( CT , bone scan ) clinical follow-up .</brief_summary>
	<brief_title>Comparison PSMA-based 18F-DCFPyL PET/CT Conventional Imaging Evaluation Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Willing able provide write informed consent Age ≥ 18 year male Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Patients start abiraterone ( naïve enzalutamide ) start enzalutamide ( naïve abiraterone ) Prior docetaxelbased chemotherapy permit require Documented metastatic prostate cancer progression assess treat oncologist either one following : Rising PSA minimum 1week interval Radiographic progression soft tissue and/or bone Ongoing androgen deprivation serum testosterone &lt; 50 ng/dL ( &lt; 1.7 nM ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Hemoglobin ≥ 90 g/L independent transfusion Platelet count ≥ 100,000/μL Serum albumin ≥ 30 g/L Serum creatinine &lt; 1.5 x ULN calculate creatinine clearance ≥ 60 mL/min Serum potassium ≥ 3.5 mmol/L Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Abnormal liver function consist follow : Serum bilirubin ≥ 1.5 x ULN ( except patient document Gilbert 's disease ) AST ALT ≥ 2.5 x ULN , ( patient know liver metastasis , AST ALT ≤ 5 x ULN allow ) Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease cardiac ejection fraction measurement &lt; 50 % baseline Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability recurrence within 12 month Known brain metastasis History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption orally administer hormonal agent . Acute toxicity due prior chemotherapy and/or radiotherapy resolve NCI CTCAE ( version 4.0 ) grade ≤ 1 ; chemotherapyinduced alopecia grade 2 peripheral neuropathy allow Current enrollment investigational drug device study , participation study within 30 day first administration hormonal agent . Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study Not willing comply procedural requirement protocol Patients partner childbearing potential willing use method birth control adequate barrier protection determine acceptable principal investigator sponsor study 13 week last study drug administration Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>